Modelling Circulating Tumour Cells for Personalised Survival Prediction in Metastatic Breast Cancer
Fig 9
Kaplan-Meier curves for Overall Survival Probability on different numbers of genes.
Patients with more than the median number of CD44+ CD47+ cells (“Double-positive high” patients) have shorter overall survival than patients with more than the median number of CD44+ CD47+ MET+ cells (“Triple-positive hogh” patients). Patients with more than the median number of CD44+ CD47+ MET+ GEN+ cells (“Quadruple-positive high” patients with GEN = MET) have the longest overall survival. The dotted lines show the median overall survival times.